UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

The FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation.

Rena D. Callahan, MD, discusses the clinical implications of the FDA approval of Dato-DXd for the treatment of patients with unresectable/metastatic TNBC.

Alexis Ann LeVee, MD, highlights breast cancer abstracts to pay attention to at the 2026 ASCO Annual Meeting.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

A new UCLA study suggests the organization of immune cells inside melanoma tumors may help show which patients benefit from combination immunotherapy

Low-cost blood tests that detect multiple blood cancers and diseases have been developed by researchers at UCLA Health.

Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

Dr Bardia discusses key findings from the phase 3 lidERA Breast Cancer study of giredestrant in estrogen receptor–positive, HER2-negative breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses the design of the ELEGANT study of elacestrant vs endocrine therapy in high-risk, ER-positive early breast cancer.

Deborah J. Wong, MD, PhD, discusses data with ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

Aditya Bardia, MD, MPH, FASCO, discussed data from the lidERA trial of giredestrant vs SOC endocrine therapy in ER-positive, HER2-negative breast cancer.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

Zev A. Wainberg, MD, discusses different palliative chemotherapy regimens, their use cases, and other recent developments in pancreatic cancer.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

The SKYSCRAPER-14 trial did not show a PFS benefit with tiragolumab plus atezolizumab and bevacizumab in untreated HCC, missing its coprimary end point.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.